1例耐药侵蚀性葡萄胎病例汇报
A Case Report of Drug Resistant Invasive Mole
DOI: 10.12677/ACM.2022.122138, PDF,   
作者: 徐胜凤, 孙小绘, 张 艳:西安医学院,陕西 西安;董 晋*:西北妇女儿童医院,陕西 西安
关键词: 滋养细胞肿瘤低危耐药高危因素治疗Trophoblastic Tumor Low-Risk Drug Resistance High-Risk Factors Treatment
摘要: 妊娠滋养细胞肿瘤(gestational trophoblastic neoplasia, GTN)是一组与妊娠相关、起源于胎盘滋养细胞的恶性肿瘤,其中包含以下几种:侵袭性葡萄胎(invasive mole, IM)、绒毛膜癌(choriocarcinoma, CCA)、上皮性滋养细胞肿瘤(epithelial trophoblastic tumor, ETT)和胎盘部位滋养细胞肿瘤(placental site trophoblastic tumor, PSTT)。随着有效化疗药物的临床应用,GTN临床治愈率达到了90%以上,但仍有10%对化疗药物不敏感的耐药患者,但目前国内外仍缺乏对耐药性GTN的诊断与治疗标准。本文对我院收治的1例低危耐药型侵蚀性葡萄胎病例进行临床分析,就其诊断、治疗、随访及转归情况,结合相关文献进行讨论,以总结经验,指导临床工作。
Abstract: Gestational trophoblastic tumor (GTN) is a group of malignant tumors related to pregnancy and originated from placental trophoblasts, including invasive mole (IM), choriocarcinoma (CCA), epithelial trophoblastic tumor (ETT) and placental site trophoblastic tumor (PSTT). With the clinical application of effective chemotherapeutic drugs, the clinical cure rate of GTN has reached more than 90%, but there are still 10% drug-resistant patients who are not sensitive to chemotherapeutic drugs. However, there is still a lack of diagnostic and treatment standards for drug-resistant GTN at home and abroad. This paper makes a clinical analysis of a case of low-risk drug-resistant invasive mole treated in our hospital, and discusses its diagnosis, treatment, follow-up and prognosis in combination with relevant literature, so as to summarize experience and guide clinical work.
文章引用:徐胜凤, 董晋, 孙小绘, 张艳. 1例耐药侵蚀性葡萄胎病例汇报[J]. 临床医学进展, 2022, 12(2): 946-951. https://doi.org/10.12677/ACM.2022.122138

参考文献

[1] Biscaro, A., Braga, A. and Berkowitz, R.S. (2015) Diagnosis, Classification and Treatment of Gestational Trophoblastic Neoplasia. Revista Brasileira de Ginecologia e Obstetrícia, 37, 42-51. [Google Scholar] [CrossRef
[2] Kohorn, E.I. (2001) The New FIGO 2000 Staging and Risk Factor Scoring System for Gestational Trophoblastic Disease: Description and Critical Assessment. International Journal of Gynecological Cancer, 11, 73-77. [Google Scholar] [CrossRef] [PubMed]
[3] Lurain, J.R. (2011) Gestational Trophoblastic Disease II: Classification and Management of Gestational Trophoblastic Neoplasia. The American Journal of Obstetrics and Gynecology, 204, 11-18. [Google Scholar] [CrossRef] [PubMed]
[4] 向阳. 宋鸿钊滋养细胞肿瘤学[M]. 第3版. 北京: 人民卫生出版社, 2011: 301.
[5] Feng, F., Xiang, Y., Li, L., et al. (2009) Clinical Parameters Predicting Therapeutic Response to Surgical Management in Patients with Chemo-Therapy-Resistant Gestational Trophoblastic Neoplasia. Gynecologic Oncology, 113, 312-315. [Google Scholar] [CrossRef] [PubMed]
[6] Locasle, J.W., Grassian, A.R., Melman, T., et al. (2011) Phosphoglycerate Dehydrogenase Diverts Glycolytic Flux and Contributes to Oncogenesis. Nature Genetics, 43, 869-874. [Google Scholar] [CrossRef] [PubMed]
[7] Kim, S.K., Jung, W.H. and Koo, J.S. (2014) Differential Expression of Enzymes Associated with Serine/Glycine Metabolism in Different Breast Cancer Subtypes. PLoS ONE, 9, e101004. [Google Scholar] [CrossRef] [PubMed]
[8] Seckl, M.J., Sebire, N.J., Fisher, R.A., et al. (2013) Gestational Trophoblastic Disease: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, i39-i50. [Google Scholar] [CrossRef] [PubMed]
[9] Hasanzadeh, M., Tabari, A., Homae, F., et al. (2014) Evaluation of Weekly Intramuscular Methotrexate in the Treatment of Low Risk Gestational Trophoblastic Neoplasia. Cancer Research and Treatment, 10, 646-650.
[10] Sita-Lumsden, A., Short, D., Lindsay, I., et al. (2012) Treatment Outcomes for 618 Women with Gestational Trophoblastic Tumours Following a Molar Pregnancy at the Charing Cross Hospital, 2000-2009. British Journal of Cancer, 107, 1810-1814. [Google Scholar] [CrossRef] [PubMed]
[11] Mousavi, A.S., Zamani, A., Khorasanizadeh, F., et al. (2014) Resistance to Single-Agent Chemotherapy and Its Risk Factors in Low-Risk Gestational Trophoblastic Neoplasms. Journal of Obstetrics and Gynaecology, 41, 776-783. [Google Scholar] [CrossRef] [PubMed]
[12] Chapman-Davis, E., Hoekstra, A.V., Rademaker, A.W., et al. (2012) Treatment of Nonmetastatic and Metastatic Low-Risk Gestational Trophoblastic Neoplasia: Factors Associated with Resistance to Single-Agent Methotrexate Chemotherapy. Gynecologic Oncology, 125, 572-575. [Google Scholar] [CrossRef] [PubMed]
[13] Goldstein, D.P. and Berkowitz, R.S. (2012) Current Management of Gestational Trophoblastic Neoplasia. Hematology Oncology Clinics of North America, 26, 111-129. [Google Scholar] [CrossRef] [PubMed]
[14] Seckl, M.J., Sebire, N.J. and Berkowitz, R.S. (2010) Gestational Trophoblastic Disease. The Lancet, 376, 717-729. [Google Scholar] [CrossRef
[15] Ngan, H.Y., Seckl, M.J., Berkowitz, R.S., et al. (2015) Update on the Diagnosis and Management of Gestational Trophoblastic Disease. International Journal of Gynecology & Obstetrics, 131, S123-S126. [Google Scholar] [CrossRef] [PubMed]
[16] 蒋芳, 向阳. 低危妊娠滋养细胞肿瘤的管理[J]. 实用妇产科杂志, 2019, 35(6): 405-408.